Clinical Trial - NCT02912572

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib in Patients With MSS Recurrent or Persistent Endometrial Cancer

Recruiting

Sponsor: Dana-Farber Cancer Institute

Collaborators: Pfizer

Information provided by (Responsible party): Principal Investigator Dana-Farber Cancer Institute Panagiotis Konstantinopoulos, MD, PhD MD, PhD

ClinicalTrials.gov Identifier: NCT02912572

Protocol Info

Short Description: Study of Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer
Long Description: A Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab (MSB0010718C) in Patients with MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab (MSB0010718C) /Talazoparib (MDV3800, BMN 673) in Patients with MSS Recurrent or Persistent Endometrial Cancer
MGH Status: Open
Sponsor: DF/HCC
Disease Program: GYN

Next Steps


If you are interested in this protocol or in other treatment options at Massachusetts General Hospital, please Request a Consultation.




Purpose

This research study is evaluating a drug called Avelumab as a possible treatment for recurrent or Metastatic Endometrial Cancer.
Condition Title Intervention Phase
Metastatic Endometrial Cancer Avelumab Talazoparib Phase 2
Study Type Interventional
Official Title A Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab (MSB0010718C) in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab (MSB0010718C) /Talazoparib (MDV3800, BMN 673) in Patients With MSS Recurrent or Persistent Endometrial Cancer

Primary Outcome Measures

Activity Of Avelumab and Avelumab plus Talazoparib In Patients With Recurrent Or Persistent Endometrial Cancer [Time Frame: 2 years] [Designated as safety issue: ]


Secondary Outcome Measures

Duration of Progression Free Survival as Assessed by RECIST 1.1 [Time Frame: 2 years] [Designated as safety issue: ]

Duration of Overall Survival [Time Frame: 2 years] [Designated as safety issue: ]

Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 [Time Frame: 2 years] [Designated as safety issue: ]

Immune-Related Objective Response as Assessed by Immune-Related RECIST (irRECIST) [Time Frame: 2 years] [Designated as safety issue: ]

Estimated Enrollment: 70
Study Start Date: November 2016
Estimated Study Completion Date: April 2024
Estimated Primary Completion Date: April 2020
Arms Assigned Interventions

Experimental:Pole Mutated Endometrial Cancer

Participants with Pole mutated endometrial cancer Avelumab will be administered intravenously twice per cycle
Drug:Avelumab
Avelumab will be administered intravenously twice per cycle Each Cycle lasts 28 days Dosage is determined by physician Premedication Antihistamine and Paracetamol will be administered prior to treatment

Experimental:MSS Endometrial Cancer

Participants with MSS mutated endometrial cancer Avelumab will be administered intravenously twice per cycle

Experimental:MSS Avelumab/Talazoparib Combination Arm

Participants with MSS mutated endometrial cancer Avelumab will be administered intravenously twice per cycle Talazoparib will be administered one time per day by mouth
Drug:Talazoparib
Talazoparib will be taken one time per day by mouth Each Cycle lasts 28 days

Eligibility

Ages Eligible for Study: N/A-N/A

Genders Eligible for Study: Female

Accepts Healthly Volunteers: No

Inclusion Criteria:

Participants must be classified into one of two cohorts of recurrent or persistent endometrial cancer of any histology:

The first cohort (MSI/POLE cohort) includes endometrial cancers that are:

  • -MSI-H as determined by immunohistochemical complete loss of expression (absence of nuclear immunoreactivity) of at least one of the mismatch repair genes MSH2, MSH6, MLH1 and PMS2. This test is now done routinely for every newly diagnosed endometrial cancer patient in most centers in the US.

And/OR:

  • -POLE-mutated, i.e. endometrial cancers known to harbor mutations in the exonuclease domain (amino acid residues 268-471) of polymerase e (POLE) as determined by targeted sequencing or other next generation sequencing assay. Any Clinical Laboratory Improvement Amendments (CLIA)-approved genomic test documenting mutations in the exonuclease domain of POLE gene (amino acid residues 268-471) in the tumor will be accepted as proof of presence of POLE mutations and will lead to classification into this patient cohort.

The second cohort (MSS cohort) includes:

  • Endometrial cancers that are MSS as determined by normal immunohistochemical nuclear expression of all the mismatch repair genes MSH2, MSH6, MLH1 and PMS2. Tumors which have not been sequenced for POLE mutations (i.e. their POLE mutations status is unknown) but are MSS, will be included in this cohort.
  • All patients must have measurable disease as defined by RECIST 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be >= 10 mm when measured by CT, MRI or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray. Lymph nodes must be > 15 mm in short axis when measured by CT or MRI.
  • Prior Therapy:
  • There is no upper limit of prior therapies but patients must have had one prior chemotherapeutic regimen for management of endometrial carcinoma. Initial treatment may include chemotherapy, chemotherapy and radiation therapy, and/or consolidation/maintenance therapy. Any platinum based chemotherapy (single agent platinum or any platinum doublet) administered in conjunction with primary radiation as a radio-sensitizer WILL be counted as a systemic chemotherapy regimen. Furthermore, patients who have only received chemotherapy in the adjuvant setting will be eligible for the study.
  • Prior hormonal therapy is allowed.
  • Patients must NOT have received any class of drugs targeted to the PD-1/PD-L1 pathway.
  • Patients must NOT have received any prior PARP inhibitor therapy.
  • Age of 18 or greater years. Because insufficient dosing or adverse event data are currently available on the use of Avelumab in participants < 18 years of age, children are excluded from the study. Endometrial cancer is very rare in the pediatric population.
  • ECOG performance status 0 or 1 (reference Appendix A for ECOG performance status criteria).
  • Availability of a formalin fixed paraffin embedded (FFPE) block of cancer tissue from the original surgery or biopsy or from a biopsy of recurrent disease.
  • Participants must have normal organ and marrow function as defined below:
  • absolute neutrophil count >1,500/mcL
  • platelets >100,000/mcL
  • hemoglobin ≥ 9g/dL
  • total bilirubin within normal institutional limits
  • AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal
  • creatinine within normal institutional limits OR
  • creatinine clearance ≥60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.

Please note: creatinine clearance (CLCR) should be estimated according to the Cockcroft-Gault formula as:

CLCR={[(140-age) × weight)]/(72 x SCR)} × 0.85 where CLCR (creatinine clearance) is measured in mL/min, age is expressed in years, weight in kilograms (kg), and SCR (serum creatinine) in mg/dL.

NOTE: Patients with moderate renal impairment (defined as an estimated creatinine clearance of 30-59 mL/min) will receive a reduced starting dose of Talazoparib at 0.75 mg PO QD.

  • Participant must not be pregnant or breastfeeding given that avelumab is an agent with unknown effects in pregnancy and breastfeeding and the potential for teratogenesis. Females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or post-menopausal (defined as ≥ 12 months with no menses without an alternative medical cause). Serum pregnancy test (for females of childbearing potential) negative at screening.
  • The effects of avelumab on the developing human fetus are unknown. For this reason and because some immunomodulatory agents are known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
  • Toxicities of prior therapy (excepting alopecia and sensory neuropathy) should be resolved to < grade 2 per the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4. All appropriate treatment areas should have access to a copy of the CTCAE version 4. A copy of the CTCAE version 4 can be downloaded from the CTEP website at: http://ctep.cancer.gov.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  • Participants who are receiving any other investigational agents.
  • Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • History of allergic reactions attributed to avelumab or any component in its formulations, or compounds of similar chemical or biologic composition to avelumab. Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3 NCI CTCAE v 4.03), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
  • Participants with a history of treatment with an anti-PD-1, anti-PD-L1, anti-CTLA-4 or other investigational agents that target immune checkpoint inhibitors.
  • Participants with a history of treatment with a PARP inhibitor.
  • Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness, which may compromise the efficacy of immunostimulatory therapy.
  • Positive test for HBV surface antigen and / or confirmatory HCV RNA (if anti-HCV antibody tested positive)
  • Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses ≤ 10 mg or 10 mg equivalent prednisone per day
  • Active infection requiring systemic therapy.
  • Current or prior use of immunosuppressive medication within 7 days prior to enrollment with the following exceptions to this exclusion criterion:
  • Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection);
  • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent;
  • Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication).
  • Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
  • Prior organ transplantation including allogeneic stem-cell transplantation.
  • Persisting Grade >=2 toxicity related to prior therapy; however, Grade 2 sensory neuropathy is acceptable.
  • Severe gastrointestinal conditions such as clinical or radiological evidence of bowel obstruction within 4 weeks prior to study entry, uncontrolled diarrhea in the last 4 weeks prior to enrollment, or history of inflammatory bowel disease.
  • Uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
  • Known alcohol or drug abuse.
  • Individuals with a history of a different malignancy are ineligible except for the following circumstances: Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: breast cancer in situ, cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
  • All other significant diseases (for example, inflammatory bowel disease, uncontrolled asthma), which, in the opinion of the Investigator, might impair the subject's tolerance of trial treatment.
  • Any psychiatric condition that would prohibit the understanding or rendering of informed consent
  • Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT02912572

Locations

  • United States, Illinois
    • University of Chicago Chicago, Illinois, United States, 60637
  • United States, Massachusetts
    • Massachusetts General Hospital Boston, Massachusetts, United States, 02114
    • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115
    • Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115

Sponsors and Collaborators

Dana-Farber Cancer Institute

Pfizer

More Information

No publications provided

Responsible Party: Principal Investigator Dana-Farber Cancer Institute Panagiotis Konstantinopoulos, MD, PhD MD, PhD
ClinicalTrials.gov Identifier: NCT02912572
Other Study ID Numbers:
Study First Received:
Last Updated:
Health Authority:

Keywords provided by Dana-Farber Cancer Institute:

Endometrial Cancer

Additional relevant MeSH terms:

Endometrial Neoplasms

Antibodies, Monoclonal

Talazoparib

Next Steps


If you are interested in this protocol or in other treatment options at Massachusetts General Hospital, please Request a Consultation.







ClinicalTrials.gov processed this data on July 18, 2019